Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26499808 | 0.82 | CHRM4 (0.43) | CHRM4CYP1A2CNR2MBOAT4LRRK2 | |
| SCHEMBL20354254 | 0.82 | CHRM4 (0.36) | CHRM4CYP1A2CNR2LRRK2SYK | |
| SCHEMBL26040948 | 0.78 | OPRK1 (0.36) | MBOAT4L3MBTL1 | |
| SCHEMBL17478633 | 0.77 | OPRK1 (0.50) | — | |
| SCHEMBL1707795 | 0.76 | ALDH1A1 (0.44) | CYP1A2LRRK2 | |
| SCHEMBL24240543 | 0.76 | OPRK1 (0.33) | L3MBTL1 | |
| SCHEMBL30867832 | 0.74 | CHRM4 (0.40) | CHRM4CYP1A2CNR2MBOAT4LRRK2 | |
| SCHEMBL25931749 | 0.73 | OPRK1 (0.42) | MAP3K12 | |
| SCHEMBL31727812 | 0.73 | CNR2 (0.34) | CHRM4CYP1A2CNR2LRRK2 | |
| SCHEMBL25925716 | 0.72 | PIK3CA (0.42) | LRRK2MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355718-A1 | Novel 5,6-Dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355718-A1 | Novel 5,6-Dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | DDX5, ZC3HAV1, MAVS | CHRM4 3626/4885CYP1A2 1160/4885CNR2 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.